Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A group of scientists led by Dr. Yamin Zhang and Dr. Colin Franz of Shirley Ryan AbilityLab and Dr. John Rogers of Northwestern University have developed a new technique. Change...
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Using MRD Status to Deescalate Multiple Myeloma Therapy
2.
A new theranostic drug targets different cancer types.
3.
Patients face high out-of-pocket costs after incident cancer diagnosis
4.
Is Exercise an Effective Treatment for Prostate Cancer?
5.
Brain cancer: a Q&A session.
1.
Modern Perspectives in Hematology for Modern Medicine
2.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
3.
Critical Care Updates on Hematopoietic Dysfunction During Prolonged Critical Illness
4.
The Risk Factors of Venous Thromboembolism and How to Lower Your Chances
5.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part III
2.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
3.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
4.
Sickle Cell Disease Explained
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge